Scottish trial shows lung cancer can be detected earlier

A groundbreaking Scottish trial has given fresh hope to potentially thousands of people who will be diagnosed with lung cancer.
Groundbreaking trial shows lung cancer can be detected earlierGroundbreaking trial shows lung cancer can be detected earlier
Groundbreaking trial shows lung cancer can be detected earlier

Results from the Early detection of Cancer of the Lung Scotland (“ECLS”) trial have shown a combination of blood tests followed by CT scanning can help detect lung cancer earlier, when surgery is still possible.

Lung cancer affects more than 5000 people every year in Scotland and within a year 4000 have died, usually because the diagnosis is made too late for curative treatment.

Hide Ad
Hide Ad

The results show a combination of blood tests followed by CT scanning can help detect lung cancer earlier, when surgery is still possible.

The trial has demonstrated a statistically significant 36 per cent reduction in late stage diagnoses of lung cancer.

Professor Frank Sullivan, Professor of Primary Care Medicine at the University of St. Andrews, the Chief Investigator for the ECLS trial, said, “I hope that the results of this trial will have globally significant implications for the early detection of lung cancer by showing how a simple blood test, followed by CT scans, is able to increase the number of patients diagnosed at an earlier stage of the disease, when surgery is still possible and prospects for survival much higher.”

Read More
Scottish woman's life saved after blood test trial picks up cancer - months befo...

Results from the trial have been published by The European Respiratory Journal in an online pre-print of the peer-reviewed results.

The ECLS trial is believed to be the largest randomised controlled trial for the detection of lung cancer using blood-based biomarkers.

The trial is supported by the University of Dundee, NHS Tayside and co-funded by Oncimmune, the Scottish Chief Scientist Office and the Scottish Government.

It involves collaborators at the University of Glasgow, with further work from the Universities of Aberdeen, St Andrews, Nottingham and Toronto, NHS Scotland, Scottish Government, The Canberra Hospital and Oncimmune, the company that developed the new blood test.

Tayside Clinical Trials Unit was responsible for trial delivery, data management and analysis.

Hide Ad
Hide Ad

To determine whether the EarlyCDT Lung blood test reduced the incidence of patients with stage III/IV lung cancer, the ECLS trial in 12,208 patients compared the use of the EarlyCDT Lung blood test followed by low dose computerised tomography (“CT”) scanning to standard clinical practice over two years.

In addition, the ECLS trial results indicated a lower rate of deaths among people in the intervention arm of the trial after two years compared with people in the control group.

Lung cancer-specific deaths were also lower in the intervention group.

This suggests that the EarlyCDT Lung test followed by CT imaging could produce a mortality benefit: the three-year follow up data which is scheduled to be imminently available, will be valuable in understanding the significance of this finding.

The paper concludes that blood-based biomarker panels, such as the EarlyCDT Lung test, followed by low dose CT, can detect stage I/II lung cancers earlier than standard NHS care.

Earlier diagnosis means that more patients should benefit from newer, more effective, chemotherapy, surgery and radiotherapy and so reduce the impact of this disease.

Further follow-up analyses will be performed after five and ten years.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

Hide Ad
Hide Ad

The dramatic events of 2020 are having a major impact on many of our advertisers - and consequently the revenue we receive. We are now more reliant than ever on you taking out a digital subscription to support our journalism.

Subscribe to and enjoy unlimited access to Scottish news and information online and on our app. Visit now to sign up.

By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

Joy Yates

Editorial Director

Related topics:



Want to join the conversation? Please or to comment on this article.